Abstract: An apparatus for use in a power delivery system, the apparatus comprising: a DC circuit breaker having first and second terminals and configured to automatically switch from a closed state to an open state during an overcurrent condition; a disconnector switch in series with the DC circuit breaker, the disconnector switch having a first terminal for connecting to a first polarity terminal of a DC power supply, a second terminal for connecting to a second polarity terminal of the DC power supply and a common terminal connected to the first terminal of the DC circuit breaker, the disconnector switch having at least a first position in which the first terminal is connected to the common terminal and a second position in which the second terminal is connected to the common terminal; and an interlock mechanism coupled to the DC circuit breaker and the disconnector switch, the interlock mechanism configured to disable the DC circuit breaker from automatically switching from the closed state to the open state during

Abstract: An apparatus for use in a power delivery system, the apparatus comprising: a DC circuit breaker having first and second terminals and configured to automatically switch from a closed state to an open state during an overcurrent condition; a disconnector switch in series with the DC circuit breaker, the disconnector switch having a first terminal for connecting to a first polarity terminal of a DC power supply, a second terminal for connecting to a second polarity terminal of the DC power supply and a common terminal connected to the first terminal of the DC circuit breaker, the disconnector switch having at least a first position in which the first terminal is connected to the common terminal and a second position in which the second terminal is connected to the common terminal; and an interlock mechanism coupled to the DC circuit breaker and the disconnector switch, the interlock mechanism configured to disable the DC circuit breaker from automatically switching from the closed state to the open state during

Abstract: Disclosed are compounds and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof that may cause degradation of various proteins e.g., IKZF2 (Helios). Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds to treat diseases and disorders associated with Helios and which may benefit from Helios degradation.

Abstract: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

Abstract: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereofs, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1 to R4, n W, X and Y are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).